Pulmonx Reports Q3 2026 Revenue Growth and Reduced Cash Burn
Pulmonx (LUNG) has returned to top-line growth, reporting third-quarter revenue of $22.8 million. The company's strategic focus on commercial realignment and expense management resulted in an 18% year-over-year decrease in operating expenses, which fell to $24.9 million. This discipline helped reduce the adjusted EBITDA loss by nearly 60% compared to the previous year. Management is prioritizing high-yielding sales accounts and has filled most open U.S. sales positions to drive domestic momentum. Additionally, Pulmonx is working to expand its total addressable market through clinical trials for AeriSeal, a specialized foam intended to seal lung air leaks. The company expects these initiatives to provide a clear pathway toward cash flow breakeven while maintaining high gross margins above 75%.
Tickers: $LUNG
Topics: cost reduction earnings report operating leverage revenue growth